The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Ibrutinib combination therapy in CLL: overview of the data so far
Ibrutinib combination therapy in an exciting therapeutic area with great potential. Many recent and ongoing studies are seeking to identify the optimal ibrutinib combinations for the treatment of chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, highlights data that was presented at the meeting which evaluated ibrutinib combination therapy for CLL, including that with venetoclax and anti-CD20 antibodies.
